Literature DB >> 35834478

Threshold of increase in oxygen demand to predict mechanical ventilation use in novel coronavirus disease 2019: A retrospective cohort study incorporating restricted cubic spline regression.

Ryo Yamamoto1, Ryo Takemura2, Asako Yamamoto2, Kazuki Matsumura1, Daiki Kaito1, Koichiro Homma1, Michihiko Wada2, Junichi Sasaki1.   

Abstract

BACKGROUND: Rapid deterioration of oxygenation occurs in novel coronavirus disease 2019 (COVID-19), and prediction of mechanical ventilation (MV) is needed for allocation of patients to intensive care unit. Since intubation is usually decided based on varying clinical conditions, such as required oxygen changes, we aimed to elucidate thresholds of increase in oxygen demand to predict MV use within 12 h.
METHODS: A single-center retrospective cohort study using data between January 2020 and January 2021was conducted. Data were retrieved from the hospital data warehouse. Adult patients diagnosed with COVID-19 with a positive polymerase chain reaction (PCR) who needed oxygen during admission were included. Hourly increments in oxygen demand were calculated using two consecutive oxygen values. Covariates were selected from measurements at the closest time points of oxygen data. Prediction of MV use within 12 h by required oxygen changes was evaluated with the area under the receiver operating curves (AUCs). A threshold for increased MV use risk was obtained from restricted cubic spline curves.
RESULTS: Among 66 eligible patients, 1835 oxygen data were analyzed. The AUC was 0.756 for predicting MV by oxygen demand changes, 0.888 by both amounts and changes in oxygen, and 0.933 by the model adjusted with respiratory rate, PCR quantification cycle (Ct), and days from PCR. The threshold of increments of required oxygen was identified as 0.44 L/min/h and the probability of MV use linearly increased afterward. In subgroup analyses, the threshold was lower (0.25 L/min/h) when tachypnea or frequent respiratory distress existed, whereas it was higher (1.00 L/min/h) when viral load is low (Ct ≥20 or days from PCR >7 days).
CONCLUSIONS: Hourly changes in oxygen demand predicted MV use within 12 h, with a threshold of 0.44 L/min/h. This threshold was lower with an unstable respiratory condition and higher with a low viral load.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35834478      PMCID: PMC9282654          DOI: 10.1371/journal.pone.0269876

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.752


Introduction

Novel coronavirus disease 2019 (COVID-19) involves lung tissue injury and often causes respiratory failure that requires mechanical ventilation (MV) [1, 2]. As the pandemic of COVID-19 has significantly depleted medical resources worldwide, the allocation of patients to appropriate places, such as the intensive care unit (ICU), general ward, and home, is needed to prevent unfavorable clinical outcomes due to insufficient treatment [3, 4]. However, quick oxygenation deterioration has been reported in patients with COVID-19 compared to other lung diseases. This situation impedes physicians from forecasting the need for MV in advance [5, 6]. While several studies have attempted to develop a prediction model for the need of MV or ICU admission, there is no well-accepted method that captures rapidly changing respiratory status in patients with COVID-19 [7-12]. Although some clinical scoring systems showed promising results with high discrimination, most use daily clinical data or those on admission and only predict deterioration within 24–48 h or thereafter [8, 9, 11, 12]. Since candidates for MV are usually on oxygen therapy and changes in respiratory status are frequently assessed within a day, estimation with such a long-term interval using a score is not practical. Moreover, although machine learning incorporating vital signs, laboratory data, and images could accurately calculate the risks for MV [7, 10] it would be difficult for most health care facilities to adopt the complicated program without trained experts. Given that the decision to intubate patients with COVID-19 largely depends on oxygenation deterioration [13], an hourly increase in oxygen demand and the amount of required oxygen would be important parameters to determine the need for MV within a short time. Accordingly, we examined the clinical consequences of patients with COVID-19 who required oxygen, using detailed electronic data obtained directly from a hospital information system that recorded various kinds of information related to oxygen therapy. We aimed to elucidate whether an increase in oxygen demand would predict MV use within 12 h, with a hypothesis that an hourly increase of supplemental oxygen higher than a specific threshold would be associated with an increased risk of MV within 12 h.

Materials and methods

Study design and setting

We conducted a single-center retrospective cohort study using data between January 2020 and January 2021, that was obtained directly from the hospital information system of Keio University Hospital, a tertiary care center in Tokyo, Japan. Sporadic COVID-19 cases were noted in Japan in January 2020. The governor of Tokyo Metropolis announced the first stay-at-home order in April 2020, which lasted one month, then the second in January 2021 [14]. There were three surges of newly diagnosed COVID-19 cases during the study period. During these surges, several academic organizations were concerned with nosocomial infection among healthcare providers during the invasive respiratory care of patients with COVID-19 [13, 15–17]; therefore, they recommended avoiding non-invasive positive-pressure ventilation (NIPPV) and high-flow nasal cannula (HFNC) for patients with COVID-19 and intubating patients with a relatively low oxygen flow threshold, such as 6–8 L/min. At the study institution, patients with mild to moderate COVID-19 who required oxygen but not MV were treated with pulmonary internal medicine physicians in general wards. Intensive care physicians treated those with severe COVID-19 who needed MV or extracorporeal membrane oxygenation in the ICU. Daily discussion between the two services was conducted regarding candidates for MV. The need for MV was decided by discussion considering respiratory status, hemodynamic stability, and the oxygen demand mentioned above. Urgent transfer of patients to the ICU due to an unexpected rapid increase in oxygen demand was conducted on a 24-hour basis depending on the agreement of the two services. Patients with severe comorbidity, such as congestive heart failure requiring oxygen and acute kidney injury requiring hemodialysis, were admitted to the ICU regardless of the severity of COVID-19.

Ethical statement

This study was approved by the Institutional Review Board of the Keio University School of Medicine (application number: 20200063) for conducting research with humans. The requirement for informed consent was waived because of the anonymous nature of the data used.

Study population

We included patients (1) aged ≥20 years, (2) diagnosed as COVID-19 with a positive reverse transcription polymerase chain reaction (RT-PCR) result for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) from an upper respiratory tract sample obtained by nasopharyngeal swab, and (3) on oxygen therapy at any time during admission. Patients who were intubated on the day of admission and those with unknown or missing data on the amount of oxygen administered were excluded. Patients who were intubated only for airway management in scheduled surgery were also excluded. All recorded data of the amount of oxygen administered were examined individually, even in the same patient. However, data on the amount of oxygen administered after MV was initiated were not included in this study.

Data collection and definition

Data were obtained from the Donner Registry, established as a real-world data registry by the Keio Donner Project, a COVID-19 research group at Keio University School of Medicine. The Donner Registry has been prospectively collecting data of patients with COVID-19 from the hospital information system with every record related to patient care. In the hospital information system, several record types, such as demographic data, auto-recorded parameters in patient-monitoring devices, descriptive records by health care providers, laboratories, images, and detailed information of when these data were saved, are archived in different systems. The Donner Registry has collected data using a data warehouse connected to all records in the hospital information system. This registry is maintained by designated data managers of the Keio Donner Project. Patient data related to this study were also obtained by the data manager, who was blinded to study analyses. Collected data included patient demographics; comorbidities, such as chronic obstructive pulmonary disease (COPD), interstitial pneumonia (IP), asthma, congestive heart failure (CHF), chronic kidney disease (CKD), cirrhosis, hypertension, and diabetes mellitus; date of a positive RT-PCR result for SARS-CoV-2; the RT-PCR quantification cycle (Ct) for SARS-CoV-2; vital signs recorded by patient-monitoring devices and health care providers; laboratory data, such as C-reactive protein (CRP), D-dimer, and glucose; medications for COVID-19 with the date of administration, including corticosteroids, remdesivir, tocilizumab, and unfractionated and low-molecular-weight heparin; the amount of oxygen administered (L/min); a descriptive record of the existence of respiratory distress; and the time (h and min) for each collected data. The time when intubation was performed, hospital length of stay, ICU length of stay, days of MV use, and survival status were also available. Change in oxygen demand was defined as a change in the amount of administered oxygen per hour, calculated using two consecutive oxygen data. Vital signs and blood glucose associated with oxygen data were determined as those measured at the closest time points prior to the oxygen data; those measured >24 h prior to the oxygen data were not used. Similarly, laboratory data associated with oxygen data were determined as those measured within three days before the oxygen data. Respiratory distress was defined as distress symptoms recorded at any time in 6-hour periods. The frequency of respiratory distress in a day was shown with a 0–4 scale, defined as the number of respiratory distress events during the past 24 h (four 6-hour periods).

Outcome measures

The primary outcome was the initiation of MV within 12 h, defined as intubation conducted within 12 h after the time point of oxygen data. Secondary outcomes included 90-day mortality and ICU- and ventilator-free days up to day 30, in which the days were counted from the day of each oxygen data.

Statistical analysis

A receiver operating curve (ROC) was used to determine the ability to predict MV use by changes in oxygen demand. Then, the area under the ROC (AUC) was compared with several adjusted models to evaluate the clinical usefulness of changes in oxygen demand. Relevant covariates were carefully selected from known or possible predictors for deteriorating oxygenation based on previous studies [18-22], including age, body mass index, comorbidities (COPD, IP, asthma, CHF, CKD, and cirrhosis), days from diagnosis of COVID-19, Ct value of initial RT-PCR for SARS-CoV-2, days from the initiation of medications for COVID-19 (corticosteroids, remdesivir, and tocilizumab), vital signs (respiratory rate [RR], heart rate, and systolic blood pressure [SBP]), laboratories (CRP, D-dimer, and glucose), and the frequency of respiratory distress in a day (0–4 scale). Adjusted models were developed using multivariate logistic regression analyses, in which variables were entered using the stepwise or simultaneous method. Variables for the full adjusted model were selected based on a point estimate for odds ratio or degree of α error. The number of selected variables were limited to avoid over-fitting; 5–10 outcomes for each potential predictor. The clinical usefulness of increased oxygen demand to predict MV use was assessed in unadjusted and adjusted models, using sensitivity, specificity, negative predictive value (NPV), and positive predictive values (PPV). Moreover, the restricted cubic spline regression model was used to identify the threshold for rapidly increasing risks for MV within 12 h [23]. The spline curve was drawn to show the risks for MV use by oxygen demand increases, then an inflection point of the spline curve was determined as the threshold, considering an increase of absolute risk from the baseline of >1%. Sensitivity analysis was conducted by excluding negative changes in oxygen demand. Furthermore, the association between secondary outcomes and the changes in oxygen demand was also analyzed using logistic and linear regression models. Subgroup analysis was performed to examine the relationship between changes in oxygen demand, clinical characteristics, and the requirement of MV. Calculating AUC and identification of the threshold of increment in oxygen based on spline curves were repeated in the subgroup of patients who were divided based on age (<65 vs. ≥65 years), the amount of administered oxygen (<4 vs. ≥4 L/min), RR (<20 vs. ≥20 /min), days from diagnosis of COVID-19 with RT-PCR (≤7 vs. >7 days), degree of viral load (Ct value of initial RT-PCR <20 vs. ≥20), and frequency of respiratory distress in a day (<2 vs. ≥2 in 0–4 scale). Descriptive statistics are presented as the median (interquartile range [IQR]) or a number (percentage). Results are shown using standardized differences and the 95% confidence interval (CI). In hypothesis testing, a two-sided α threshold of 0.05 was considered statistically significant. Considering the low number of included data points, optimism was evaluated with bootstrapping (resampling the model 1000 times) to obtain a corrected AUC [24]. All statistical analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC).

Results

Patient characteristics

Among 285 patients with COVID-19 during the study period, 72 adults had oxygen therapy and met all the inclusion criteria. A total of 6 patients were intubated on the day of admission; therefore, 66 patients were eligible for this study. Among 2524 oxygen data available in included patients, 689 were excluded from the analyses because they were after the MV initiation. The patient flow diagram is shown in Fig 1.
Fig 1

Patient flow diagram.

Among 285 patients with COVID-19 during the study period, 72 adult patients had oxygen therapy and met all the inclusion criteria. A total of 6 patients were intubated on the day of admission, and therefore 66 patients were eligible for this study. Among 2524 oxygen data available in included patients, 689 were excluded from the analyses because they were those after MV initiation. Abbreviations: COVID-19, novel coronavirus disease 2019; MV, mechanical ventilation.

Patient flow diagram.

Among 285 patients with COVID-19 during the study period, 72 adult patients had oxygen therapy and met all the inclusion criteria. A total of 6 patients were intubated on the day of admission, and therefore 66 patients were eligible for this study. Among 2524 oxygen data available in included patients, 689 were excluded from the analyses because they were those after MV initiation. Abbreviations: COVID-19, novel coronavirus disease 2019; MV, mechanical ventilation. Patient characteristics are shown in Table 1. Eleven patients (16.7%) required MV during admission and used MV. Patients treated with MV were older and had lower Ct values (higher viral load) on RT-PCR for SARS-CoV-2 (18 vs. 24) than those who did not require MV. Among 1835 oxygen data analyzed in this study, MV was initiated within 12 h after 34 (1.9%) oxygen data. Clinical information associated with each oxygen data is summarized in Table 2. When MV was initiated in the next 12 h, patients had a higher increase in oxygen demand (0.25 vs. 0.00 L/min/h) and higher RR, SBP, D-dimer, and glucose than when MV was not needed in the next 12 h. Days from the positive PCR test, admission, and initiation of corticosteroid, remdesivir, and unfractionated heparin were fewer when MV was required in the next 12 h, compared with when it was not required (4 vs. 7 days from PCR, 5 vs. 11 days from admission, 1 vs. 6 days from corticosteroids, 1 vs. 5 days from remdesivir, and 0 vs. 6 days from unfractionated heparin, respectively). Conversely, the frequency of respiratory distress was comparable regardless of the need for MV in the next 12 h.
Table 1

Characteristics of patients with COVID-19 on oxygen therapy.

CharacteristicsIntubationNo intubationp valueStandardized Difference
Case1155
Age, years, median (IQR)75 (67–81)64 (54–76)0.0440.773
Sex, male, n (%)10 (90.9%)39 (70.9%)0.2640.526
BMI, median (IQR)25 (22–26)26 (22–29)0.2650.378
Comorbidity, n (%)4 (36.4%)19 (34.5%)1.0000.038
 COPD0 (0.0%)2 (3.6%)
 Interstitial pneumonia0 (0.0%)2 (3.6%)
 Asthma0 (0.0%)0 (0.0%)
 CHF0 (0.0%)2 (3.6%)
 CKD0 (0.0%)0 (0.0%)
 Cirrhosis0 (0.0%)0 (0.0%)
 Hypertension4 (36.4%)11 (20.0%)
 Diabetes mellitus0 (0.0%)6 (10.9%)
Smoking history, n (%)2 (18.2%)10 (18.2%)1.0000.009
Ct value on RCP for SARS-CoV-2a, median (IQR)18 (14–24)24 (20–31)0.0021.042
Treatment, n (%)
 Corticosteroid6 (54.5%)22 (40.0%)0.5070.294
 Tocilizumab0 (0.0%)8 (14.5%)0.3340.582
 Remdesivir5 (45.5%)20 (36.4%)0.7350.186
 Unfractionated heparin8 (72.7%)25 (45.5%)0.1850.577

COVID-19 = Novel coronavirus disease 2019, IQR = interquartile range, COPD = chronic obstructive pulmonary disease, CHF = congestive heart failure, CKD = chronic kidney disease, Ct = cycle of quantification, PCR = polymerase chain reaction, and SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

aWhen multiple samples were obtained at the same time, Ct values were averaged.

Table 2

Clinical information associated with changes in oxygen demand.

Intubation within 12 hNo intubation within 12hp-valueStandardized Difference
Number of data points341801
Changes in oxygen demand, L/min/h, median (IQR)0.25 (0.00–0.67)0.00 (0.00–0.00)<0.0010.709
Vital signs, median (IQR)
 Respiratory rate, /min21 (16–26)18 (16–20)0.0030.500
 Heart rate, /min72 (65–78)75 (64–86)0.4340.145
 SBP, mmHg130 (126–134)118 (106–130)<0.0010.766
Days from positive PCR, median (IQR)4 (1–9)7 (2–16)0.0020.713
Days from admission, median (IQR)5 (1–15)11 (5–45)0.0050.534
Duration of treatment, days from, median (IQR)
 Corticosteroid1 (0–5)6 (5–20)0.0090.826
 TocilizumabN/A3 (0–5)N/AN/A
 Remdesivir1 (0–5)5 (1–14)0.0250.812
 Unfractionated heparin0 (0–2)6 (1–14)<0.0011.070
Laboratory, median (IQR)
 CRP1.4 (1.0–1.7)2.5 (0.9–8.2)0.1060.192
 D-dimer9.2 (4.9–18.8)3.6 (1.5–8.1)<0.0010.885
 Glucose148 (99–166)176 (136–238)0.0140.481
Frequency of respiratory distressa, median (IQR)1 (0–2)1 (0–2)0.1080.289

IQR = interquartile range, SBP = systolic blood pressure, PCR = polymerase chain reaction, and CRP = C-reactive protein.

aFrequency of respiratory distress were shown using 0–4 scale.

COVID-19 = Novel coronavirus disease 2019, IQR = interquartile range, COPD = chronic obstructive pulmonary disease, CHF = congestive heart failure, CKD = chronic kidney disease, Ct = cycle of quantification, PCR = polymerase chain reaction, and SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2. aWhen multiple samples were obtained at the same time, Ct values were averaged. IQR = interquartile range, SBP = systolic blood pressure, PCR = polymerase chain reaction, and CRP = C-reactive protein. aFrequency of respiratory distress were shown using 0–4 scale.

Prediction of MV use and secondary outcomes

Accuracy in predicting the need of MV within 12 h by the changes in oxygen demand was assessed in several logistic regression models. In these analyses, the full adjusted model included RR, Ct value of PCR for SARS-CoV-2, and days from positive PCR as covariates. AUC was 0.756 (95% CI, 0.662–0.851) in the simple model using only changes in oxygen demand, 0.888 (0.856–0.919) in a combination model using both amounts and changes in oxygen demand, and 0.933 (0.908–0.958) in the full adjusted model (Fig 2 and Table 3). All models had >99% of NPV at the Youden index, whereas PPV was only 7%–14%. Sensitivity analyses found similar results, in which negative changes in oxygen demand were excluded (S1 Fig and Table 3). Optimism was evaluated using bootstrapping in each model, which identified corrected AUCs similar to original AUCs.
Fig 2

Receiver operating curve for prediction of mechanical ventilation use by changes in oxygen demand.

Changes in oxygen demand to predict MV use within 12 h were evaluated by ROCs in several models as follows: simple model only using increments in oxygen demand (AUC 0.756 [0.662–0.851]); combination model using both amounts and increments in oxygen demand (AUC 0.888 [0.856–0.919]); and a fully adjusted model including amounts and increments in oxygen demand, RR, Ct value of PCR for SARS-CoV-2, and days from positive PCR (0.933 [0.908–0.958]). Abbreviations: ROC, Receiver operating curve; MV, mechanical ventilation; AUC, area under the ROC; RR, respiratory rate; Ct, quantification cycle; PCR, polymerase chain reaction; and SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Table 3

Accuracy for prediction of MV usage by changes in oxygen demand.

Model #Variables in modelAUC95% CIOptimismCorrected AUCSensitivitySpecificityNPVPPV
1Changes in oxygen demand0.7560.662–0.8510.0010.75669.7%81.9%99.3%6.8%
2Amounts and changes of oxygen demand0.8880.856–0.9190.0020.88587.9%79.6%99.7%7.5%
3Amounts and changes of oxygen demand with other predictorsa0.9330.908–0.9580.0050.92496.8%83.5%99.9%13.5%
4Increments in oxygen demandb0.7740.689–0.8600.0010.77576.7%77.2%99.3%6.8%
5Amounts and increments of oxygen demand0.8730.834–0.9110.0020.87086.7%76.4%99.6%7.4%
6Amounts and increments of oxygen demand with other predictorsa0.9270.897–0.9570.0070.92096.4%82.5%99.9%14.4%

MV = mechanical ventilation, AUC = area under the receiver operating characteristic curve, CI = confidence interval, NPV = negative predictive value, and PVV = positive predictive value. Sensitivity, specificity, NPV, and PPV were calculated with Youden Index.

aOther predictors included Ct value of polymerase chain reaction (PCR), days from positive PCR, and respiratory rate (RR).

bAnalyses were performed after excluding negative changes in oxygen demand.

Logit-transformed predictive rate for MV usage within 12 h was calculated in each model as follows:

(1) 0.97 × changes in oxygen − 4.19

(2) 0.56 × changes in oxygen + 0.21 × amounts of oxygen − 4.98

(3) 0.54 × changes in oxygen + 0.21 × amounts of oxygen − 0.12 × Ct value − 0.12 × days from PCR + 0.02 × RR − 1.70

(4) 0.95 × changes in oxygen − 4.15

(5) 0.55 × changes in oxygen + 0.20 × amounts of oxygen − 4.87

(6) 0.52 × changes in oxygen + 0.20 × amounts of oxygen − 0.12 × Ct value − 0.14 × days from PCR + 0.01 × RR − 1.47

Receiver operating curve for prediction of mechanical ventilation use by changes in oxygen demand.

Changes in oxygen demand to predict MV use within 12 h were evaluated by ROCs in several models as follows: simple model only using increments in oxygen demand (AUC 0.756 [0.662–0.851]); combination model using both amounts and increments in oxygen demand (AUC 0.888 [0.856–0.919]); and a fully adjusted model including amounts and increments in oxygen demand, RR, Ct value of PCR for SARS-CoV-2, and days from positive PCR (0.933 [0.908–0.958]). Abbreviations: ROC, Receiver operating curve; MV, mechanical ventilation; AUC, area under the ROC; RR, respiratory rate; Ct, quantification cycle; PCR, polymerase chain reaction; and SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. MV = mechanical ventilation, AUC = area under the receiver operating characteristic curve, CI = confidence interval, NPV = negative predictive value, and PVV = positive predictive value. Sensitivity, specificity, NPV, and PPV were calculated with Youden Index. aOther predictors included Ct value of polymerase chain reaction (PCR), days from positive PCR, and respiratory rate (RR). bAnalyses were performed after excluding negative changes in oxygen demand. Logit-transformed predictive rate for MV usage within 12 h was calculated in each model as follows: (1) 0.97 × changes in oxygen − 4.19 (2) 0.56 × changes in oxygen + 0.21 × amounts of oxygen − 4.98 (3) 0.54 × changes in oxygen + 0.21 × amounts of oxygen − 0.12 × Ct value − 0.12 × days from PCR + 0.02 × RR − 1.70 (4) 0.95 × changes in oxygen − 4.15 (5) 0.55 × changes in oxygen + 0.20 × amounts of oxygen − 4.87 (6) 0.52 × changes in oxygen + 0.20 × amounts of oxygen − 0.12 × Ct value − 0.14 × days from PCR + 0.01 × RR − 1.47 A restricted cubic spline curve was drawn in Fig 3. Based on the inflection point in the spline curve, a 0.44 L/min/h increase in oxygen demand was identified as the threshold to predict MV in the next 12 h, where the NPV was 98.5%. With a higher oxygen increase than the threshold, the probability of MV use linearly increased.
Fig 3

Restricted cubic spline curves and threshold of increments in oxygen demand.

The restricted cubic spline curve was shown for the risks of MV use within 12 h by increments in oxygen demand, with dashed lines for 95% CI. Based on the inflection point, which considers an increase of absolute risk from the baseline by >1% (horizontal dashed line), 0.44 L/min/h of increment in oxygen demand was identified as the threshold to predict mechanical ventilation in the next 12 h. With a higher increment of oxygen than the threshold, the probability of MV use linearly increased. Abbreviations: MV, mechanical ventilation; CI, confidence interval.

Restricted cubic spline curves and threshold of increments in oxygen demand.

The restricted cubic spline curve was shown for the risks of MV use within 12 h by increments in oxygen demand, with dashed lines for 95% CI. Based on the inflection point, which considers an increase of absolute risk from the baseline by >1% (horizontal dashed line), 0.44 L/min/h of increment in oxygen demand was identified as the threshold to predict mechanical ventilation in the next 12 h. With a higher increment of oxygen than the threshold, the probability of MV use linearly increased. Abbreviations: MV, mechanical ventilation; CI, confidence interval. Analyses on secondary outcomes revealed that increments in oxygen demand were associated with increased 90-day mortality but not with ICU- and ventilator-free days that were counted from the day of each oxygen data (S1 Table).

Subgroup analyses

In the subgroup analyses (Table 4), the high accuracy in predicting the requirement of MV by the increments in oxygen demand was observed: >0.9 of AUCs and >98% of NPV at the thresholds were found in most subgroups (Table 4).
Table 4

Prediction of MV use by increments in oxygen demand in subgroups.

AUC95% CIThreshold (L/min/h)aSensitivitySpecificityNPVPPV
Age
 <65 years0.9900.978–1.0000.3366.7%88.9%99.4%8.9%
 > = 65 years0.9400.915–0.9660.5033.3%88.4%98.2%6.3%
Amount of oxygen
 <4 L/min0.9900.978–1.0000.3366.7%91.9%99.9%2.4%
 > = 4L/min0.8690.821–0.9180.4040.7%75.6%94.9%10.3%
Respiratory Rate
 <20 /min0.9630.943–0.9830.7530.8%92.9%99.1%5.1%
 > = 20 /min0.8870.832–0.9420.2564.7%81.6%97.9%14.9%
Days from positive PCR
 < = 7 days0.9170.875–0.9580.3347.8%86.4%98.2%9.7%
 > 7 days0.9800.961–0.9991.0042.6%92.6%99.3%6.0%
Viral load
 Ct <200.9040.855–0.9540.2268.4%81.4%98.2%14.6%
 Ct > = 200.9360.887–0.9841.0018.2%94.2%99.0%3.4%
Frequency of respiratory distress (0–4 scale)
 < 20.9180.877–0.9590.6729.4%92.3%98.7%6.3%
 > = 20.9530.908–0.9980.2561.5%87.0%98.6%13.1%

MV = mechanical ventilation, AUC = area under the receiver operating characteristic curve, CI = confidence interval, NPV = negative predictive value, PVV = positive predictive value, PCR = polymerase chain reaction, and Ct = cycle of quantification.

aThreshold was obtained from an infection point in the spline curve in each subgroup.

MV = mechanical ventilation, AUC = area under the receiver operating characteristic curve, CI = confidence interval, NPV = negative predictive value, PVV = positive predictive value, PCR = polymerase chain reaction, and Ct = cycle of quantification. aThreshold was obtained from an infection point in the spline curve in each subgroup. The threshold for increased risk of MV use was lower in a patient with a RR ≥20/min than those with a RR <20/min, as well as days from positive PCR ≤7 than >7, high viral load (Ct < 20) than low viral load (Ct ≥ 20), and high frequency of respiratory distress (≥2 in 0–4 scale) than low frequency (<2 in 0–4 scale). Conversely, thresholds were similar regardless of the amount of administered oxygen (0.33 L/min/h in low amount oxygen use [<4 L/min] vs. 0.40 L/min/h in high amount oxygen use [≥4 L/min]).

Discussion

In this retrospective study, hourly changes in oxygen demand had a high discrimination power to predict MV use, particularly when incorporated with the amount of oxygen, RR, Ct value of PCR, and days from positive PCR. Notably, an increment in oxygen demand higher than 0.44 L/min/h significantly increased the risk for the requirement of MV in the next 12 h. Several reasons would be considered behind the high predictive ability for the need for MV in this study. First, hourly changes in oxygen demand would be a highly reliable predictor of MV use because most physicians intubate patients when oxygen demand increases, particularly with an accelerated increase [25]. Second, the current study analyzed all data related to oxygen therapy at any given time point, which would have captured rapidly changing respiratory status of COVID-19 [26]. While preexisting scores, such as Respiratory Rate Oxygenation and National Early Warning Score, utilized clinical parameters only at defined time points, including on admission and/or a few days after admission [9, 10], each patient in this study had detailed data with nearly 30 different time points. Third, several clinically valuable covariates were also obtained directly from the hospital information system and analyzed along with the changes in oxygen demand. Given that auto-recorded vital signs, days from positive PCR or medications, and frequency of respiratory distress are important information for physicians to decide intubation [2, 19, 26, 27], utilizing such variables with oxygen data would result in high predictive power. According to the current results, using the increments in oxygen demand to forecast the need for MV has various merits. As the prediction window was 12 h in this study, alternation of administered oxygen in the daytime would help physicians determine to transfer a patient to the ICU before the night. In addition, considering that a greater influence on the prediction of MV use was observed in the changes in oxygen demand than the amount of oxygen, an increment in the dose of oxygen would be useful even when a high amount of oxygen is administered. Moreover, NPV for the initiation of MV is as high as >99.5% even in the simple model only utilizing changes in oxygen demand; therefore, the possibility of intubation within 12 h would be denied solely by the lower increment of oxygen than the threshold. To clinically adopt the threshold of increments in oxygen demand, patient characteristics should be considered because various thresholds for increasing risks for MV use were obtained in subgroup analyses. As the thresholds were lower (0.25 L/min/h) among patients with tachypnea (RR ≥20) and high frequency of respiratory distress (≥2 in 0–4 scale), patients with an unstable respiratory condition would need intubation even with low increments in oxygen demand. However, it should be noted that the difference in the amount of oxygen did not affect the threshold of increments in oxygen demand. Moreover, given that thresholds as high as 1.00 L/min/h were observed in patients with low viral load (Ct ≥20) and a considerable duration passed after the positive PCR (>7 days), such a population can stay at general wards even when oxygen demand is increasing, such as a gradual increase by 3–4 L/min in a day time. The results in this study must be interpreted within the context of the study design. During the study period, NIPPV and HFNC were not used in patients with COVID-19. Therefore, the thresholds to predict the need for NIPPV or HFNC would be different [28, 29], although intolerance of simple oxygen administration through face masks would be highly predicted by the increments in oxygen demand. Another limitation is that the study was conducted at a single center with limited sample size. Although the changes in oxygen demand would influence more the prediction of the requirement of MV than the amounts of oxygen, thresholds obtained in this study should be validated in future studies with large sample sizes. Moreover, in the pandemic of COVID-19, several novel medications have been developed and reported to improve outcomes. Considering that days from the initiation of medications for COVID-19 were fewer when MV was used in the next 12 h than when MV was not used, some medications would affect the relationship between increments of oxygen demand and prediction of intubation. Finally, as we investigated only patients with COVID-19, our results cannot be generalized to potential candidates for MV who need oxygen due to other diseases.

Conclusions

The hourly changes in oxygen demand highly predict the need for MV in the next 12 h, particularly when incorporated with the amount of oxygen, RR, Ct value of PCR, and days from positive PCR. While the threshold for increasing risks for MV use was determined as 0.44 L/min/h, a lower threshold was observed in patients with an unstable respiratory condition, such as high RR and high frequency of respiratory distress. Patients with low viral load or >7 days after the positive PCR would tolerate considerable increments of oxygen demand. The threshold identified in this study would be useful for appropriately allocating patients to ICU in regions where resources are overwhelmed due to pandemic of COVID-19, while the generalizability of threshold should be validated by a multi-center trial with large sample size.

Receiver operating curve for sensitivity analysis.

Sensitivity analysis was conducted by excluding negative changes in oxygen demand. Increments in oxygen demand to predict mechanical ventilation use within 12 h was evaluated by ROCs in several models as follows: simple model only using increments in oxygen demand (AUC 0.774 [0.689–0.860]); combination model using both amounts and increments in oxygen demand (AUC 0.873 [0.834–0.911]); and a fully adjusted model including amounts and increments in oxygen demand, RR, Ct value of PCR for SARS-CoV-2, and days from positive PCR (0.927 [0.897–0.957]). Abbreviations: ROC, Receiver operating curve; AUC, area under the ROC; RR, respiratory rate; Ct, quantification cycle; PCR, polymerase chain reaction; and SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. (TIFF) Click here for additional data file.

Changes in oxygen demand and secondary outcomes.

(DOCX) Click here for additional data file. 29 Apr 2022
PONE-D-22-06778
Threshold of Increase in Oxygen Demand to Predict Mechanical Ventilation Use in Novel Coronavirus Disease 2019: A Retrospective Cohort Study Incorporating Restricted Cubic Spline Regression
PLOS ONE Dear Dr. YAMAMOTO, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jun 13 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Muhammad Tarek Abdel Ghafar, M.D Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf. 2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability. Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized. Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access. We will update your Data Availability statement to reflect the information you provide in your cover letter. 3. One of the noted authors is a group or consortium [Keio Donner Project]. In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address. 4. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: I Don't Know Reviewer #3: Yes Reviewer #4: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Appreciating your work, I would like to forwards the following minor comments and suggestions: 1. Please include a separate ethical statement in your methods section, that clearly highlights the consent measures used, and the ethical procedures followed. 2. In your conclusion segment, I believe it will give your findings more impact if you can phrase them in terms of public and global health impact. Reviewer #2: SARS-COV-2 is primarily a respiratory pathogen, hospitalized patients with covid-19 who decompensate need assistant ventilation. Many patients requiring hospitalization have caused a great strain on hospital resources. A simple tool that can effectively predict the potential need of mechanical ventilation would ensure better use of existing resources. The paper by R Yamamoto et al presented a well-written article addressing a very practical question – the prediction of mechanical ventilation among patients with the covid-19 disease. The authors aimed to determine thresholds of increase in oxygen demand to predict mechanical ventilation use within 12 h. The title and abstract are appropriate for the content of the text. The article is well constructed. The main strength of this paper is that it addresses a timely question and provides a promising result for a solution. At the same time, the limited study sample (66 patients included// 11 patients intubated) and relatively early intubation decision (oxygen flow requirements 6-8L) is a problem in terms of extracting wide conclusions from the work. Some questions the authors might consider: - The list of comorbidities does not include hypertension or diabetes. These conditions may place a patient with covid-19 at a higher risk of severe illness. - The definition of “severe comorbidity” (row 128-129) was not clear. Are these patients included in the study? - Low molecular weight heparin (LMWH) is not included in the list of administrated medications. Patients with covid 19 may trigger a coagulopathy state and affect changes in oxygen demand. Reviewer #3: Thanks for giving me the chance to review the above mentioned article. I enjoyed reading this new concept and hoped that it helped you care for your patients during the crisis. Definitely, you need more numbers to empower the results and more than one center for sake of generalizability. Reviewer #4: Thanks to authors. I have completed the evaluation of the article entitled "Threshold of Increase in Oxygen Demand to Predict Mechanical Ventilation Use in Novel Coronavirus Disease 2019: A Retrospective Cohort Study Incorporating Restricted Cubic Spline Regression”. I have not observed that grammatical errors in this study. It is a nice study written on determining the oxygen need in COVID-19. Best regards ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No Reviewer #4: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.
9 May 2022 A point-by-point response letter is attached to the manuscript. Submitted filename: DonnerOxyIntubate_response_RY050122.docx Click here for additional data file. 30 May 2022 Threshold of Increase in Oxygen Demand to Predict Mechanical Ventilation Use in Novel Coronavirus Disease 2019: A Retrospective Cohort Study Incorporating Restricted Cubic Spline Regression PONE-D-22-06778R1 Dear Dr. YAMAMOTO, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Muhammad Tarek Abdel Ghafar, M.D Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: All questions and comments have been addressed. No further feedback or suggestions. I thank the authors for making the time to integrate these comments into their manuscript to better the scientific content. Reviewer #2: Thanks for giving me the chance to review the above mentioned article entitled "Threshold of Increase in Oxygen Demand to Predict Mechanical Ventilation Use in Novel Coronavirus Disease 2019: A Retrospective Cohort Study Incorporating Restricted Cubic Spline Regression”. The manuscript is improved, my comments have been addressed in the revised version of the article. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No 6 Jul 2022 PONE-D-22-06778R1 Threshold of Increase in Oxygen Demand to Predict Mechanical Ventilation Use in Novel Coronavirus Disease 2019: A Retrospective Cohort Study Incorporating Restricted Cubic Spline Regression Dear Dr. Yamamoto: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Prof Muhammad Tarek Abdel Ghafar Academic Editor PLOS ONE
  29 in total

1.  Internal validation of predictive models: efficiency of some procedures for logistic regression analysis.

Authors:  E W Steyerberg; F E Harrell; G J Borsboom; M J Eijkemans; Y Vergouwe; J D Habbema
Journal:  J Clin Epidemiol       Date:  2001-08       Impact factor: 6.437

2.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.

Authors:  Safiya Richardson; Jamie S Hirsch; Mangala Narasimhan; James M Crawford; Thomas McGinn; Karina W Davidson; Douglas P Barnaby; Lance B Becker; John D Chelico; Stuart L Cohen; Jennifer Cookingham; Kevin Coppa; Michael A Diefenbach; Andrew J Dominello; Joan Duer-Hefele; Louise Falzon; Jordan Gitlin; Negin Hajizadeh; Tiffany G Harvin; David A Hirschwerk; Eun Ji Kim; Zachary M Kozel; Lyndonna M Marrast; Jazmin N Mogavero; Gabrielle A Osorio; Michael Qiu; Theodoros P Zanos
Journal:  JAMA       Date:  2020-05-26       Impact factor: 56.272

3.  Management of COVID-19 Respiratory Distress.

Authors:  John J Marini; Luciano Gattinoni
Journal:  JAMA       Date:  2020-06-09       Impact factor: 56.272

Review 4.  High-Flow, Noninvasive Ventilation and Awake (Nonintubation) Proning in Patients With Coronavirus Disease 2019 With Respiratory Failure.

Authors:  Suhail Raoof; Stefano Nava; Charles Carpati; Nicholas S Hill
Journal:  Chest       Date:  2020-07-15       Impact factor: 9.410

5.  Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.

Authors:  Yeming Wang; Dingyu Zhang; Guanhua Du; Ronghui Du; Jianping Zhao; Yang Jin; Shouzhi Fu; Ling Gao; Zhenshun Cheng; Qiaofa Lu; Yi Hu; Guangwei Luo; Ke Wang; Yang Lu; Huadong Li; Shuzhen Wang; Shunan Ruan; Chengqing Yang; Chunlin Mei; Yi Wang; Dan Ding; Feng Wu; Xin Tang; Xianzhi Ye; Yingchun Ye; Bing Liu; Jie Yang; Wen Yin; Aili Wang; Guohui Fan; Fei Zhou; Zhibo Liu; Xiaoying Gu; Jiuyang Xu; Lianhan Shang; Yi Zhang; Lianjun Cao; Tingting Guo; Yan Wan; Hong Qin; Yushen Jiang; Thomas Jaki; Frederick G Hayden; Peter W Horby; Bin Cao; Chen Wang
Journal:  Lancet       Date:  2020-04-29       Impact factor: 79.321

Review 6.  Knowledge translation tools to guide care of non-intubated patients with acute respiratory illness during the COVID-19 Pandemic.

Authors:  David Leasa; Paul Cameron; Kimia Honarmand; Tina Mele; Karen J Bosma
Journal:  Crit Care       Date:  2021-01-08       Impact factor: 9.097

7.  COVID-IRS: A novel predictive score for risk of invasive mechanical ventilation in patients with COVID-19.

Authors:  José Antonio Garcia-Gordillo; Antonio Camiro-Zúñiga; Mercedes Aguilar-Soto; Dalia Cuenca; Arturo Cadena-Fernández; Latife Salame Khouri; Jesica Naanous Rayek; Moises Mercado
Journal:  PLoS One       Date:  2021-04-05       Impact factor: 3.240

8.  Early Prediction of COVID-19 Ventilation Requirement and Mortality from Routinely Collected Baseline Chest Radiographs, Laboratory, and Clinical Data with Machine Learning.

Authors:  Abdulrhman Fahad Aljouie; Ahmed Almazroa; Yahya Bokhari; Mohammed Alawad; Ebrahim Mahmoud; Eman Alawad; Ali Alsehawi; Mamoon Rashid; Lamya Alomair; Shahad Almozaai; Bedoor Albesher; Hassan Alomaish; Rayyan Daghistani; Naif Khalaf Alharbi; Manal Alaamery; Mohammad Bosaeed; Hesham Alshaalan
Journal:  J Multidiscip Healthc       Date:  2021-07-30

9.  Validation of a Crisis Standards of Care Model for Prioritization of Limited Resources During the Coronavirus Disease 2019 Crisis in an Urban, Safety-Net, Academic Medical Center.

Authors:  Albert Nadjarian; Jessica LeClair; Taylor F Mahoney; Eric H Awtry; Jasvinder S Bhatia; Lisa B Caruso; Alexis Clay; David Greer; Karan S Hingorani; L F B Horta; Michel Ibrahim; Michael H Ieong; Thea James; Matthew H Kulke; Remington Lim; Robert C Lowe; James M Moses; Jaime Murphy; Ala Nozari; Anuj D Patel; Brent Silver; Arthur C Theodore; Ryan Shufei Wang; Ellen Weinstein; Stephen A Wilson; Anna M Cervantes-Arslanian
Journal:  Crit Care Med       Date:  2021-10-01       Impact factor: 9.296

10.  Time course of risk factors associated with mortality of 1260 critically ill patients with COVID-19 admitted to 24 Italian intensive care units.

Authors:  Alberto Zanella; Gaetano Florio; Massimo Antonelli; Giacomo Bellani; Angela Berselli; Tiziana Bove; Luca Cabrini; Eleonora Carlesso; Gian Paolo Castelli; Maurizio Cecconi; Giuseppe Citerio; Irene Coloretti; Daniele Corti; Francesca Dalla Corte; Edoardo De Robertis; Giuseppe Foti; Roberto Fumagalli; Massimo Girardis; Riccardo Giudici; Lorenzo Guiotto; Thomas Langer; Lucia Mirabella; Daniela Pasero; Alessandro Protti; Marco V Ranieri; Roberto Rona; Luigia Scudeller; Paolo Severgnini; Savino Spadaro; Nino Stocchetti; Martina Viganò; Antonio Pesenti; Giacomo Grasselli
Journal:  Intensive Care Med       Date:  2021-08-09       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.